...

A multi-national, multi-centre, prospective, single-arm, observational, non-interventional post-authorisation safety study to investigate long-term safety of Sogroya (somapacitan) in adults with growth hormone deficiency (AGHD) under normal routine practice (REAL 7)

To investigate long-term safety of Sogroya (somapacitan) therapy in patients with AGHD in the setting of routine clinical practice with special focus on neoplasms and diabetes mellitus type 2.

Why this Research Matters

We are doing this study to collect information about how safe and effective Sogroya (somapacitan) is, when used for treatment of people with Adult Growth Hormone Deficiency (AGHD). This study has a special focus on neoplasms and diabetes mellitus type 2. Sogroya (somapacitan), which is prescribed by physicians, is commercially available in the U.S., as well as in many other countries and has been approved by regulatory authorities.

Who can Participate

Adult

Diagnosis of Adult Growth Hormone Deficiency (AGHD). Currently being treated or planned to start treatment with Sogroya (somapacitan).

Study ID

Protocol Number: 23-1727
More information available at ClinicalTrials.gov: NCT05718570

Meet the Team

Image of Principal Investigator

Christie Turin More, MD

Principal Investigator

Categories

Locations